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The potential of zalcitabine (ddC) to act as an ionizing radiation response modifier was tested on exponentially growing human cancer 
cells in vitro. Two human cell lines, WiDr (colon) and MCF-7 (breast) were exposed to ddC at 10 p M concentration for various lengths 
of tide (18, 24, 48 and 72 h). On the WiDr cell line the dual effect of concentration and duration of exposure prior to irradiation was 
investigated. Experimental endpoints were clonogenicity and viability, as measured by colony formation assay (CFA) and MTT assay 
respectively. The impact on cell-cycle distribution prior to irradiation was assessed by flow cytometry using a double labeling technique 
(propidium iodide and bromodeoxyuridine pulse label). A significant reduction in surviving fraction and viability was observed for 
WiDr-cells irradiated after pre-exposure to 10 pM for 18, 48 and 72 h as compared to corresponding irradiated controls. At lower 
concentrations (1 and 5 pM), the radiosensitizing effect was only significant after a 72-h exposure (assessed by CFA). For MCF-7, ddC 
induced a significant modification of the dose response only with 24 and 48 h preincubation. However, the overall effect was less 
pronounced as compared to WiDr. Cell-cycle analysis showed accumulation in S-phase, 48 and 72 h after treatment with 10 p M  ddC in 
the WiDr cells, with a progressive shift to late S-phase as shown by the biparametric analysis. The degree of radiosensitization is cell-line 
dependent with the most important sensitization observed on the most <<radioresistant cell line>>, ix., the cell line with the lowest alpha 
value and highest SF 2 (WiDr). For WiDr, radiosensitization by ddC depends on the duration of exposure and the concentration of the 
drug. 
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Accepted 10 December 1996 
Nucleoside analogues (NA) were first investigated in the 
1960s as potential biological response modifiers (BRM) 
of radiation response (1 - I 1). Djordjevic (1) and Erikson 
(2)  showed the capacity of bromodeoxyuridine and iodo- 
deoxyuridine to act as non-hypoxic radiosensitizers. The 
effect was thought to be related to  the competition of 
halogenated nucleosides with native dTMP for subse- 
quent phosphorylation and incorporation into DNA (7). 
Arabinofuranosyladenine (Ara-A) and arabinofuranosyl- 
cytosine (Ara-C) were shown by Iliakis to  interact at the 
level of post-irradiation fixation of potentially lethal 
damage repair (5).  Kim et al. demonstrated a negative 
feedback on de novo synthesis of D N A  and RNA, redis- 
tribution of cells in G2 and subsequent radiosensitization 
by 6-thioguanine (8). However, not all N A  will lead to 
radiosensitization. According to specific experimental 
conditions, some of them are potential radioprotectors 
(12). 
0 Scandinavian University Press 1997. ISSN 0284-1 86X 
More recently, drugs such as 2’-deoxy-2’(fluorome- 
thylene) cytidine (FMdC) and 2‘,2’-difluoro-Tdeoxy- 
cytidine (dFdC) were described as BRM for radiation 
response in vitro (13). On the other hand, the triphos- 
phate of ddC (ddCTP) ha3 been shown to inhibit DNA- 
polymerase gamma and beta resulting in a n  impact a t  the 
level of mitochondria1 DNA synthesis and DNA repair 
respectively (14). Therefore we decided to  test this deoxy- 
cytidine derivative as a BRM, and to  investigate the effect 
of exposure duration and concentration. 
MATERIAL AND METHODS 
Chemicals and drugs 
Zalcitabine (ddC) was kindly provided by Bristol-Myers/ 
Switzerland. DMSO, MTT and propidium iodide were 
purchased from Sigma Chemie (Buchs, Switzerland). 
Pepsin was purchased from Merck AG (Switzerland). 
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zolium bromide), a yellow tetrazolium salt, was dissolved 
at a concentration of 5 mg/ml in RPMI medium without 
phenol red, filtered and frozen for stockage. 
Cell culture 
Media and supplements were purchased from Gibco BRL 
(Basel, Switzerland). Fetal Calf Serum was obtained from 
Fakola AG (Basel, Switzerland).Two cell lines, WiDr and 
MCF-7, were purchased from the American Type Culture 
Collection (ATCC Rockville, MD) and grown on media as 
specified by ATCC. WiDr, a human primary adenocar- 
cinoma of the rectosigmoid colon, was grown on minimum 
essential medium (MEM) with 0.85gll NaHC03, supple- 
mented with 10Yn FCS, 1Yn non-essential amino acids, 2 
mM L-glutamine, and 1% penicillin-streptomycin solution 
(pen-strep). The plating efficiency (PE) in these conditions 
was 99Oh. MCF-7, a human breast cancer cell line, was 
grown in MEM with 10%) FCS, 0.5% pen-strep, 1% L-glu- 
tamine, 1 mM non-essential amino acids, 1 mM sodium 
pyruvate, and 10 pg/ml bovine insulin (90Y0). The PE for 
MCF-7 was approximately 40%). 
For the MTT assay, the WiDr cells were grown on 
RPMI-I 640 medium (without L-glutamine and phenol 
red), supplemented with 10% FCS and 1% pen-strep. 
Phenol red was suppressed in order to avoid the use of 
hydrochloric acid in the final solvent, which is known to 
alter the spectral properties of the formazan. 
Irradiation lclonogenic assay 
The cells were irradiated at room temperature with an Oris 
IBL 637 cesium source at a dose rate of 80.2 cGy/min 
(dose range 1 to 10 Gy with 1 Gy dose increment). Prior to 
irradiation exponentially growing cells were exposed to 
varying concentrations of ddC (1.5 and 10 pM) for WiDr, 
and to a single concentration of 10 pM for MCF-7. The 
exposure time ranged from 18 to 72 h. For the 48- and 
72-h preirradiation exposure, the medium was changed 
every 24 h and supplemented with freshly prepared ddC. 
After trypsinization the cells were seeded in 100x20 mm 
Falcon Primaria culture dishes at adequate low density. 
Irradiation was done three hours after plating in order to 
allow cell attachment. For each irradiation dose four 
dishes were used for control and four dishes for ddC 
pretreated cells in parallel. An equivalent number of dishes 
were used to estimate baseline PE without radiation expo- 
sure. The clones (at least 50 surviving cells) were counted 
manually after fixation with 70'1/0 ethanol and staining with 
crystal violet. 
The dose-modifying factor has been defined as the ratio 
of the surviving fraction of unexposed irradiated cells to 
the surviving fraction of ddC-treated and irradiated cells. 
These calculations were done at the 50% survival level 
(DMF-50) and at the 10Y0 survival level (DMF-10). 
IrradiationlMTT assay 
The MTT assay was used because it is a rapid and 
semi-automatable technique. The original assay was 
modified according to Denizot & Lang (15) and Twenty- 
man & Luscombe (16). The assay was performed with 
WiDr only. The cells were plated in a Falcon Primaria 96 
well microplate at an appropriate concentration (4 300 
cells/well in 200 p L  medium). The assay was carried out in 
one half the area of the microtitre plate for the control and 
in the other half for the drug-exposed cells. The outer 
edges of the microtitre plate were filled with Earle's Bal. 
Salt (Gibco BRL) in order to avoid dehydration effects. 
Three hours after plating, the plates were irradiated at 
doses ranging from I to 10 Gy with a 1 Gy dose incre- 
ment. To eliminate the apparent resistant tail at high dose, 
owing to the presence of doomed cells, some plates were 
irradiated at 15 Gy. The viability obtained at 15 Gy was 
subtracted from both treatment and control values at 
lower dose levels. After 72 h incubation the culture 
medium was removed, and the MTT procedure performed. 
The plates were read at a wavelength of 570 nm on a 
Spectra SLT (Tecan Ag., Hombrechtikon-Switzerland) 
plate recorder with the reference set at 690 nm. 
Cell-cycle distribution f low cytometry 
The cells were prepared and exposed to ddC in exactly the 
same conditions as for the clonogenic assay. The cells were 
labeled with bromodeoxyuridine 30 min, then trypsinized 
and fixed in 70% ethanol. Cells were stained with propid- 
ium iodide for total DNA content. The cell suspension was 
stored in the dark at 4°C prior to the analysis. Biparamet- 
ric flow cytometry yielded DNA content (red fluorescence; 
propidium iodine) and S-fraction (green fluorescence). The 
S-phase was arbitrarily divided into two equal sections to 
estimate accumulation in early and late S-phase compared 
to controls. 
We analyzed 15 000 events, acquired on list mode using 
Multiplus (Phoenix Flow, San Diego, California). 
Data analysis 
Statistical analysis was carried out with the Statview soft- 
ware package on a Macintosh SE/30 computer. The curve 
fitting of the natural logarithm of SF (SF=surviving 
fraction) versus dose in Gy was done by a second degree 
polynomial regression analysis yielding the alpha and beta 
values for each experimental setting. The DMF-10 (dose- 
modifying factor at the 10% survival level) and DMF-50 
(dose-modifying factor at the 50% survival level) were 
calculated using the fraction of the calculated SF of the 
control versus drug-exposed cells, after introducing the 
respective alpha and beta values obtained from each re- 

































Acta Oncologica 36 (1997) Cell line specific radiosensitizing effect of zalcitabine 20 I 
Table 1 
EJfect on the surviving,fraction at 2 Gy (SF-2): preradiation exposure to 10 ptM ddC (72 11)  of two cell lines from human origin (WiDr, colon 
cancer cell h e ;  MCF- 7, breast cancer ceN line). The tabulated values are the mean values and corresponding standard errors calculated from 
e.uperiments repeated at least thrice. The p-value (Student's t-test, two-sided) in the last column is issued from comparing all the experimental 
points (control us. ddC) for the radiation reponse curve from 0 to 10 
A ( C )  YerSUS Time (h) Control'c' ddC-I0 pM* 
Alpha SF-2 (Yo) Alpha SF-2 (Yo) p-value 
WiDr 
18 0.24 f 0.07 72.6 f 3.8 0.32 k 0.07 66.3 f 2.7 ~ 0 . 0 5  
48 0.15 f 0.04 73.9 & 2.4 0.43 f 0.04 64.5 f 0.7 < 0.05 
72 0.11 f0 .03  86.4 f 2.1 0.42 f 0.03 60.3 k 2.4 < 0.05 
24 0.9 f 0.25 28.4 & 3.3 0.76 f 0.28 27.3 f 3.6 <0.05 
48 0.67 f 0.19 31.2 f 3.2 0.60 f 0.3 29.8 k 2.2 <0.05 
72 0.60 f 0.20 31.1 f 2.5 0.31 f 0.28 30.9 & 5.8 0.4 
MCF-7 
The experiments were carried out simultaneously for 
control and drug-exposed cells for the whole range of 
doses in Gy (range 1-10 Gy), and each experimental set 
was repeated three times. Therefore, in order to compare 
survival data a two-sided paired t-test was used. A differ- 
ence was considered statistically significant if a 0.05 p- 
value was reached. Standard errors were calculated and 
plotted on the corresponding figures. 
RESULTS 
Clonogenic ussuy 
Treatment of WiDr and MCF-7 with up to 10 p M  of ddC 
did not result in a significant change in the PE as com- 
pared to untreated controls. After 72 h exposure to 10 pM 
ddC, the surviving fraction at 2 Gy, calculated taking into 
account the corresponding baseline PE, was significantly 
reduced for pretreated WiDr (Table 1). For MCF-7, there 
was a difference at 24 and 48 h but this difference disap- 
peared at 72 h. Taking the complete set of SF values (SF% 
from 1 to 10 Gy), the difference between pretreated cells 
(10 p M  of ddC) and corresponding controls was statisti- 
cally significant for WiDr at all exposure times, whereas 
for MCF-7 the values were only significantly different at 
24- and 48-h exposure times (Table 1). However, the effect 
of 10 p M  ddC was most pronounced for the WiDr-cells 
with the lowest alpha value and the highest SF 2, i.e., the 
most 'radioresistant' cell line (WiDr). 
Subsequent experiments aimed at evaluating the impor- 
tance of preincubation time and dose of ddC were there- 
fore conducted only with WiDr. Reduction of the 
concentration of ddC from 10 to 1 p M  at 72 h yielded a 
reduced radiosensitizing capacity. However, even at 1 pM 
concentration, we observed an increase in alpha and a 
reduced SF2 (see Table 2). At these lower concentrations 
of ddC (1 and 5 pM/48 h), a shorter exposure duration did 
not result in significant radiosensitization. The expected 
reduction in the radiosensitizing effect by lowering the 
concentration of ddC to 1 and 5 p M  was counterbalanced 
by the prolongation of exposure to 72 h, resulting in 
significant sensitization even at low dose ddC (see Table 
2). The importance of exposure duration was also illus- 
trated at 10 pM ddC. The efficacy of 10 p M  ddC as a 
radiosensitizer, especially in WiDr cells, is summarized in 
Table 3. Both DMF-10 and DMF-50 values are listed for 
both WiDr and MCF-7 cells at different exposure dura- 
tions. The highest DMF value was obtained in WiDr cells 
exposed for 72 h to 10 p M  ddC and reached 1.84. 
Post-radiation exposure to very low dose ddC (0.5 pM) 
again yielded a small but statistically significant radiosensi- 
tizing effect (DMF-10 = 1.10 and DMF-50 = 1.23). Higher 
concentrations of ddC applied after irradiation induced a 
major reduction of PE that did not allow meaningful 
conclusions. As was the case with pre-irradiation exposure, 
the radiosensitization was mainly observed in the initial 
part of the dose-response curve. 
MTT-USSUY 
The viability test (MTT), as well as the flow cytometry, 
was performed on the cell line with the largest sensitization 
by ddC, i.e., WiDr. The viability of the cells exposed to up 
to 10 p M  ddC was not significantly different from that of 
controls. For irradiated WiDr, the preirradiation exposure 
to 10 p M  ddC consistently and significantly lowered the 
observed viability as compared to controls for all dura- 
tions of exposure tested (p<0.05). As observed in the 
clonogenic assays, the duration of exposure to ddC prior 
to irradiation significantly influenced the observed effect 
on viability with the most pronounced reduction of viabil- 
ity observed with a 72 h exposure to ddC. 
Flow cytometry 
The cell-cycle effects of ddC prior to irradiation were 
analyzed on WiDr, at the single concentration of 10 p M  
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Table 2 
Impact of duration of exposure and concentration of ddC on the radiation response of exponentially growing WiDr in vitro. The tabulated 
values are the mean values and corresponding standard errors calculated from experiments repeated at least thrice. The p-value (Student’s 
t-test, two-sided) in the last column is issued from comparing all the experimental points (control versus ddC)for the radiation reponse curve 
from 0 to 10 Gy 
~ ~ 
A ( C )  Versus * Time (h) Control“) ddC* 
Alpha SF-2 (“h) Alpha SF-2 (Yo) p-value 
ddC-10 fiM 
18 0.24 f 0.07 72.6 k 3.8 
48 0.15 k 0.04 73.9 k 2.4 
72 0.1 1 f 0.03 86.4 k 2.1 
48 0.23 k 0.06 67.7 5 3.1 
72 0.17 k0.08 75.9 f 3.6 
72 0.17 f 0.08 75.9 k 3.6 
ddC- 5 p M 
ddC-l P M  
ric analysis (double staining with PI and BrdUrd) showed 
significant differences in cell-cycle distribution as com- 
pared to controls (Figure). At 24 h after subcultivation, 
there seemed to be a delayed progression through the cell 
cycle with significantly more control cells having pro- 
gressed to late S and G2 + M as compared to ddC-treated 
cells. At 48 and 72 h, there was a significant accumulation 
of cells treated with ddC 10 mM in the S-phase. By 
dividing the green-labeled population midway between 
GO-G1 and G2 + M, an estimate was made of early S (ES) 
and late S (LS). At 48 h, both ES and LS were significantly 
increased by ddC, whereas at 72 h the overall S-phase 
increase was essentially due to LS accumulation. 
DISCUSSION AND CONCLUSIONS 
Cure from cancer undoubtedly requires local control. Ra- 
diation therapy aims at increasing local tumor control, but 
for a variety of tumors local recurrence remains a keystone 
in disease progression. To increase the efficacy of local 
radiotherapy, the intensity of the radiation treatment 
should be enhanced. For the radiation oncologist the Holy 
Grail is the quest for modalities that can enhance selec- 
tively the radiation effect on tumor cells while sparing 
normal tissues. Nucleoside analogues (NA) are interesting 
drugs because they should be preferentially incorporated in 
actively dividing tissues (6, 17). From 1960 on, different 
investigators have been testing NA as potential modifiers 
of radiation response. In vitro experiments yielded interest- 
ing results, especially for bromo- and iododeoxyuridine, 
ara-A and ara-C, fludarabine, chloro- and fluorodeoxycy- 
Table 3 
____ ~ 
WiDr 72 h 48 h 18 h 
DMF-I0 1.33 1.26 I .05 
DMF-50 1.84 1.57 1.2 
MCF-7 72 h 48 h 24 h 
DMF-I0 I .04 1.04 1.06 
DMF-50 1.02 0.95 1.05 
0.32 0.07 66.3 k 2.7 < 0.05 
0.43 0.04 64.5 f 0.7 <0.05 
0.42 f 0.03 60.3 k 2.4 <0.05 
0.28 + 0.08 68.6 2.7 0.45 
0.36 f 0.09 69.4 f 2 < 0.05 
0.29+0.ll 68.8 f 6 < 0.05 
tidine and thioguanine (1-11, 18-21). Some of these NA 
are being actively investigated in clinical trials as radiosen- 
sitizers (22, 23). 
Research in the field of NA has developed tremendously 
since their application in the context of AIDS and AIDS- 
related complex. Some of these NA were found to behave 
as potential modifiers of chemotherapy. Azydothymidine 
(AZT), acting on thymidine kinase and hence blocking the 
salvage pathway, has been shown to act synergistically 
with 5-fluorourad (24). Recently, we published data on 
the effect of AZT on the radiation response of WiDr and 
HeLa cells in vitro. The expected sensitization did not 
occur. Azydothymidine seems to be able to reduce the 
radiation effect in vitro (12). 
Zalcitabine (ddC) is particularly interesting because of 
its widespread clinical use in AIDS and AIDS-related 
complex (25-27). This deoxycytidine is known to have 
effects similar to, although less toxic than, AZT. It sup- 
presses HIV- 1 replication by inhibiting viral reverse tran- 
scriptase and/or by terminating viral DNA synthesis. It is, 
however, 10 times more potent than AZT, and does not 
have the same toxicity profile, and does not show cross-re- 
sistance; the reason why it has been extensively studied in 
monotherapy or in combination with AZT (25). It is 
known to reduce the activity of the DNA polymerase beta 
and inhibit the mitochondria1 DNA polymerase gamma 
(14). The S-phase accumulation observed might be an 
illustration of this effect on DNA polymerase. Moreover, 
it has been shown that ddC is able to decrease the direct 
buffering of calcium by mitochondria (28). It is potentially 
interesting to investigate whether this alteration of Ca+ + 
might result in a modification of Ca+ + dependent endonu- 
clease activity and related apoptosis. 
On the other hand, halogenated derivatives of deoxycy- 
tidines (5-bromo-Tdeoxycytidine and 5-chloro-2’deoxy- 
cytidine) have been shown to act as radiosensitizers and 
cytotoxic agents (9). Their mechanism of action is at the 










































2 0  30  4 0  5 0  6 0  70 8 0  
Hours 
30 I I 
h 0 G2+M/Co 0 G2+M/ddC 
o ! .  , . , r I . , .  I .  
2 0  30  4 0  5 0  6 0  7 0  80 
Hours 
0 ES-CO 
0 ES-ddC 20 





12 I * I . I ' , ' , .  
2 0  30  4 0  5 0  60 70 8 0  
Hours 
Figure. I .  Cell-cycle distribution of exponentially growing unirradiated WiDr exposed to 10 p M  ddC (closed symbols) for 24, 48 and 72 
h, compared to corresponding controls (open symbols). Medium and drug change was done every 24 h. Upper left: number of GO-GI 
cells in 'YO as a function of time to exposure in hours. Upper right: number of cells in early S-phase (ES). Lower left: number of cells in 
G2 + M. Lower right: number of cells in late S-phase (LS). 
thymidine kinase (salvage pathway). The phosphorylated 
halogenated deoxyuridine will be incorporated as a 
thymidine analogue after a further two phosphorylations. 
These compounds are cytotoxic, and there is a concentra- 
tion dependent decrease in cell survival. Their capacity to 
act as radiosensitizers is undoubtedly higher than that of 
ddC when one compares the obtained DMF values. Zal- 
citabine, as a deoxycytidine, has no cytotoxic effect per se 
at concentrations up to 10 pM in vitro. Nevertheless, a 
significant increase in radiation sensitivity was observed 
which seemed cell-line dependent. The dose modifying 
effect was most pronounced in the cell line with the lowest 
alpha value (WiDr). In this <<resistant cell line>>, the 
observed effect increased with increasing concentration of 
ddC (range 1 to 10 pM) and prolonged exposure (range 18 
to 72 h). The correlation between exposure time concentra- 
tion and radiosensitization has already been observed for 
halogenated pyrimidines such as BrdUrd and Ird Urd (1 1. 
29). 
Cell synchronization, although observed in certain con- 
ditions does not in fact support the observed effect. The 
redistribution of cells in S-phase was not consistently 
found at all time points, nor in all cell lines. The increase 
in the S-phase fraction of the non-synchronized population 
of WiDr cells exposed for 48 h and 72 h to 10 pM ddC 
resulted in a significant radiosensitization. Biparametric 
analysis revealed progresssive accumulation of cells in the 
late S-phase especially at 72 h, although a significant 
global S-phase accumulation had already occurred at 48 h. 
The increase in radiation sensitivity and S-phase accumu- 
lation seems contradictory (30). It is as yet unclear whether 
the S-phase accumulation may be a result of direct interac- 
tion of ddC with thymidine kinase (TIC) which is required 
in cell proliferation or by inhibition of DNA polymerase 
gamma (14, 31). On the other hand, the known inhibitory 
effect on DNA polymerase beta and hence the reduction 
of DNA repair may explain the marked change in the 
alpha component of the dose response. 
Zalcitabine (ddC) applied to exponentially growing tu- 
mor cells acts as a radiosensitizer in vitro. The importance 
of the radiosensitization depends upon the cell line, and 
































204 P. A.  Coucke ei al. Acta Oncologica 36 (1997) 
alpha value, in agreement with the results of Miller et al. 
(32). Using WiDr, a ddC-sensitive cell line, we demon- 
strated the importance of dose and  timing of the drug. The 
effect appears on the initial slope of the most radioresis- 
tant cell line. The reduction of the shoulder width without 
a significant change in beta value (the dose-squared term) 
implies an increase in the single hit character of low LET 
radiation (20). More radiosensitive cell lines such as MCF- 
7 show less or no enhancement. However, a steep dose- 
response relationship will make small changes difficult to 
detect, especially considering the sensitivity of the methods 
used. The major advantage of  ddC,  however, is its poten- 
tial t o  act as a radiosensitizer a t  low concentrations and 
especially a t  clinical-relevant dose levels, provided the ex- 
posure duration is long enough. A t  these concentrations 
there is n o  significant cytotoxic effect per se (no significant 
change in plating efficiency). This, of  course, could poten- 
tially result in an interesting therapeutic index if there is no 
major bone marrow toxicity, which should be tested first 
on  an animal model. 
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